Keytruda showed a significant survival benefit over Tecentriq and Opdivo in older adults with metastatic NSCLC, with a 33% ...
University of Queensland researcher Arutha Kulasinghe studied lung biopsies from the tumours of almost 250 patients with non-small cell lung cancer across Australia, the United States and Europe.
Libtayo plus chemotherapy is potentially more cost-effective than Keytruda plus chemotherapy for advanced NSCLC, offering lower costs and higher QALYs. The study's model, based on clinical trial data, ...
Novel combination achieves 60.8% response rate and 90.2% disease control rate in first-line non-small cell lung cancer (1L NSCLC) Notably, ~92% of all evaluable patients have PD-L1 TPS <50%, including ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Commission (EC) ...
This is the first and only subcutaneous immune checkpoint inhibitor in Europe that a health care provider can administer in ...
Merck announces EC approves SC administration of Keytruda for all adult indications approved in the European Union: Rahway, New Jersey Thursday, November 20, 2025, 14:00 Hrs [IST] ...
As the race to develop oncology bispecifics heats up, Pfizer has offered a first look at its strategy to dethrone Keytruda and establish its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback